Ardelyx, Inc.

ARDX

US0396971071

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 13:00:00 2024-07-03 EDT			5-day change	1st Jan Change
5.32 ^USD	+0.76%		-12.93%	-14.19%

07-03	HC Wainwright Adjusts Ardelyx's Price Target to $10 From $13, Keeps Buy Rating	MT
07-02	Piper Sandler Downgrades Ardelyx to Neutral From Overweight, Cuts Price Target to $7 From $15; Shares Plunge	MT

Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment

July 02, 2024 at 07:06 am

July 2 (Reuters) - Ardelyx Inc:

* ARDELYX: CHOSE NOT TO APPLY TO INCLUDE XPHOZAH IN CMS END-STAGE RENAL DISEASE PROSPECTIVE PAYMENT SYSTEM TRANSITIONAL DRUG ADD-ON PAYMENT ADJUSTMENT Source text for Eikon: Further company coverage:

Latest news about Ardelyx, Inc.

HC Wainwright Adjusts Ardelyx's Price Target to $10 From $13, Keeps Buy Rating	07-03	MT
Piper Sandler Downgrades Ardelyx to Neutral From Overweight, Cuts Price Target to $7 From $15; Shares Plunge	07-02	MT
Wedbush Adjusts Ardelyx's Price Target to $11 From $15, Keeps Outperform Rating	07-02	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	07-02	MT
Ardelyx Opts Out of CMS Payment Adjustment for Xphozah; Shares Plunge Pre-Bell	07-02	MT
Sector Update: Health Care	07-02	MT
Ardelyx Opts Out of CMS Payment Adjustment for Xphozah	07-02	MT
Transcript : Ardelyx, Inc. - Special Call	07-02
Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment	07-02	RE
Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH	07-02	CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 2000 Value Index	06-30	CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 3000 Value Index	06-30	CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 2500 Value Index	06-30	CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index	06-30	CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 3000E Value Index	06-30	CI
Ardelyx Shares Fall; Chief Commercial Officer Resigns	05-24	MT
Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer	05-23	CI
Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing	05-09	MT
Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing	05-09	MT
Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing	05-07	MT
Ardelyx Shares Rise After Q1 Beat	05-03	MT
Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating	05-03	MT
Top Premarket Gainers	05-03	MT
Transcript : Ardelyx, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M	05-02	MT

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ardelyx, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.32 USD

Average target price

10.94 USD

Spread / Average Target

+105.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARDELYX, INC.	-14.19%	1.24B
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+17.67%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.47%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-46.81%	14.89B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B

Bio Therapeutic Drugs

Ardelyx, Inc.

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment

Latest news about Ardelyx, Inc.

Chart Ardelyx, Inc.

Company Profile

Income Statement Evolution

Ratings for Ardelyx, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs